[State of the meningococcal disease in Navarra].

An Sist Sanit Navar

Seccción de Vigilancia y Control Epidemiológico, Instituto de Salud Pública, Pamplona.

Published: March 2004

The incidence of meningococcal disease in Navarra and Spain is determined for the 1991-1997 period, with a detected density of incidence of 5.46 per 100,000 in the 1987-1991 period. In Navarra the incidence in the 1991-1997 period was of 3.26 per 100,000 inhabitants, of which 1.91 per 100,000 corresponded to serogroup B, 0.77 per 100,000 corresponded to serogroup C, and a rate of 0.57 per 100,000 were non-grouped. During the year 1997 (weeks 1 to 35) the accumulated incidence in the period of MD serogroup C was of 0.38 per 100,000 (2 cases), the Ratio of Rates Navarra/Spain was 0.21. Considering that the last case of MD occurred in week 8, in an adult woman of 39 years and nonexistence of serogroup A in Navarra, it can bi concluded that there is no justification for a strategy of mass or routine vaccination with respect to meningococcus C.

Download full-text PDF

Source
http://dx.doi.org/10.23938/ASSN.0628DOI Listing

Publication Analysis

Top Keywords

meningococcal disease
8
1991-1997 period
8
100000 corresponded
8
corresponded serogroup
8
0
6
[state meningococcal
4
disease navarra]
4
incidence
4
navarra] incidence
4
incidence meningococcal
4

Similar Publications

Background: Invasive meningococcal disease is a devastating public health problem for the African meningitis belt. We assessed the safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, Y, W, and X (NmCV-5) relative to a licensed, quadrivalent meningococcal conjugate vaccine (MenACWY-TT) when co-administered with routine childhood vaccines at ages 9 months and 15 months.

Methods: In this single-centre, double-blind, randomised, controlled, phase 3, non-inferiority trial, children aged 9-11 months who had completed their local infant Expanded Program on Immunization (EPI) vaccines were recruited at the Centre pour le Développement des Vaccins in Bamako, Mali.

View Article and Find Full Text PDF

While antimicrobial resistance in Neisseria meningitidis, the causative agent for invasive meningococcal disease (IMD), is rare, some meningococcal isolates in Japan were resistant to ciprofloxacin and penicillin (PCG). Among 290 meningococci isolated from 2003 to 2020 in Japan, four PCG resisitant (PCG) meningococci were found but showed the minimum inhibitory concentration (MIC) with 0.5 μg/mL at a maximum due to mutation in penA gene that encodes penicillin-binding protein 2 (PBP2).

View Article and Find Full Text PDF

Background And Objective: Invasive meningococcal disease (IMD) is an uncommon but serious disease associated with a risk of death and severe long-term sequelae, impacting both patients and their caregivers. Productivity losses due to IMD have not previously been comprehensively evaluated in the USA. This study evaluated both market and non-market productivity losses to better estimate the economic burden of IMD in the USA.

View Article and Find Full Text PDF

Two New Kindreds with Complete Factor D Deficiency.

Eur J Immunol

March 2025

Department of Immunology, Assistance Publique- Hôpitaux de Paris (AP-HP), Georges Pompidou European Hospital, Paris, France.

Inborn deficiencies of the alternative pathway (AP) of the complement system have been associated with life-threatening infections, mainly by encapsulated bacteria. Complete factor D (FD) deficiencies have been reported in only seven families in the literature. We report two new cases of biochemically and genetically confirmed complete FD deficiency, including the first in a Down syndrome patient.

View Article and Find Full Text PDF

Geographical and temporal variations of serogroups and clonal types of involved in culture-confirmed invasive meningococcal disease in Canada, 2015-2023.

J Med Microbiol

March 2025

Vaccine Preventable Bacterial Diseases, Science, Reference and Surveillance Directorate, National Microbiology Laboratory Branch, Pubic Health Agency of Canada, Winnipeg, Manitoba, Canada.

Invasive meningococcal disease (IMD) is a nationally notifiable illness in Canada due to its potential severity and transmissibility. Vaccination strategies differ by province/territory and are informed by changes in the antigenic characteristics of circulating strains. Though IMD statistics are tracked at a provincial/territorial level, there is a lack of published data characterizing trends in the epidemiology of this disease at a national level.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!